Ann: ONJCRI Evaluates Monepantel Anti-Cancer Mechanism, page-65

Nice thought but it wouldn't be my choice given we are giving up 25% of the company and access to all its IP without an ability to properly determine the full value of MPL. I would think R&D funding from a major pharma for specific purpose and then they have the rights for commercialization with a royalty/commission back to PAA for the life of the drug. This would be a similar deal to that with Elanco but allowing/ensuring more input and oversight of the R&D by the major pharma to ensure a successful outcome.

Using such a model would allow PAA to develop MPL for multi purposes with various pharmas (+ funding) thus monetizing the full value of MPL for PAA and all shareholders.

Just a another thought on extracting maximum value from MPL which given the most recent announcement seems to be positively expanding its application. Interested to hear others opinions

GLTAH...Allez, Allez, Allez, P....A....A..!!!